1. Home
  2. PLTK vs CAPR Comparison

PLTK vs CAPR Comparison

Compare PLTK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Playtika Holding Corp.

PLTK

Playtika Holding Corp.

HOLD

Current Price

$3.14

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$31.59

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLTK
CAPR
Founded
2010
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
PLTK
CAPR
Price
$3.14
$31.59
Analyst Decision
Buy
Strong Buy
Analyst Count
6
8
Target Price
$5.04
$44.63
AVG Volume (30 Days)
1.5M
1.3M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
12.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,755,400,000.00
N/A
Revenue This Year
$2.60
N/A
Revenue Next Year
$2.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.08
N/A
52 Week Low
$2.64
$4.30
52 Week High
$5.59
$40.37

Technical Indicators

Market Signals
Indicator
PLTK
CAPR
Relative Strength Index (RSI) 56.62 58.24
Support Level N/A $25.33
Resistance Level $3.82 $36.49
Average True Range (ATR) 0.13 1.91
MACD 0.05 0.01
Stochastic Oscillator 84.35 73.85

Price Performance

Historical Comparison
PLTK
CAPR

About PLTK Playtika Holding Corp.

Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. The company offers both Mobile and Web-based platforms.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: